Everolimus under the trade name of Afinitor is a cancer medicine that interferes with the growth of cancer cells and slows their spread in the body. This medication is marketed by Novartis under the trade names Zortress (USA) and Certican (Europe and other countries) in transplantation medicine, and as Afinitor and Votubia in oncology. It is also available from Biocon under the trade name Evertor. Afinitor is the derivative of sirolimus that works as an inhibitor of mammalian target of rapamycin (mTOR). It was approved for the treatment of a certain type of breast cancer.
This mTOR inhibitor was approved for the treatment of
- Hormone Receptor-Positive, HER2-Negative Breast Cancer
- Advanced Kidney Cancer
- Advanced Pancreatic Neuroendocrine Tumor
- Advanced GI/Lung NET
- Renal Angiomyolipoma with Tuberous Sclerosis Complex
- SEGA with Tuberous Sclerosis Complex(TSC)
- Epilepsy with Tuberous Sclerosis Complex
- Advanced Renal Cell Carcinoma (RCC)
Mechanism of action
Everolimus is an inhibitor of mTOR that blocks the regulating cancer cell proliferation’s gene. Everolimus as a type of signal transduction inhibitor treatment stops some of the signals within cells that make them grow and divide. So it helps to stop cancer from growing or may slow it down.
NORMAL TSC GENE FUNCTION
- Genes TSC1 and TSC2 produced TSC1/TSC2, the hamartin/tuberin protein complex.
- In normal cells, the TSC1/TSC2 complex inhibits mTOR.
- The TSC1/TSC2 complex helps control the process of cell growth and proliferation by inhibiting mTOR.
LOSS OF TSC GENE FUNCTION
- In TSC patients, the TSC1/TSC2 genes are lost or deactivated, resulting in hyperactivation of mTOR.
- This hyperactivation leads to dysregulated cell growth and uncontrolled cell proliferation and hamartoma formation throughout the body.
TREATMENT WITH AFINITOR
- AFINITOR reduces cell growth, proliferation, and angiogenesis. It blocks the effects of TSC1/TSC2 genes loss.
The second main reason for cancer-related death among women, after lung cancer is breast cancer. Novartis pharmaceutical company faces stiff competition in the cancer field from Roche Holding AG, the world leader in oncology. So this field is an important one for Novartis which remains bullish about prospects for its blockbuster cancer drug Afinitor. This drug achieved sales of $1.58 billion in a year, despite competitors lining up to challenge its market position.
A quarter of Afinitor sales related to Kidney or renal cancer accounts and about 50 percent is devoted to breast cancer. New products such as Pfizer’s Ibrance challenges the breast cancer market and also pharmaceutical exporter in Turkey but Afinitor is continuing to grow strongly, with sales rising 19 percent in constant currency terms to $423 million that making it an important plank of Novartis’s big cancer drug portfolio. Thomson Reuters Cortellis believes that Consensus forecasts point to sales peaking at $2.06 billion in 2018.
According to GBI Research, the global breast cancer therapeutics market is set to increase in value from $10.4 billion in 2014 to $17.2 billion by 2021, at a CAGR of 7.3%. According to the latest report of the company, the main reason of this strong growth will be substantial increases in the prevalence of breast cancer, with rates of the disease expected to rise due to an aging population, changing lifestyles and higher survival rates. It is also stated the market and also Turkish pharmaceutical distributors will face some limitations due to patent expirations for a number of key drugs, including Afinitor, Avastin, and Herceptin. But, using branded therapies combination in both the early-stage and metastatic settings will increase the annual cost of therapy and offset the impact of patent expires.
It is also expected that the global breast cancer therapeutics market will exhibit an 8.4% CAGR from 2015 to 2023, rising to a revenue opportunity of US$16.21 bn by 2023. Afinitor price is around $ 15,685.
Geographically, North America is the most important region in the global market that is mainly due to a well-established medical insurance structure in key country-wide markets in the region, rising prevalence of breast cancer and an increase in R&D funding through public and private sectors. It is also expected that this region remains the top-grosser, accounting for over 36.2% of the overall market by 2023. Probably the Asia-Pacific region will grow at a significant pace, over this period.
Breast Cancer market received A total of 70 new pieces during the fourth quarter of 2015. Totally, Afinitor with 17 new pieces held the largest promotional volume.
Dano Health as a pharmaceutical wholesale in turkey can provide Afinitor for all hospitals and health clinics.